-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration showed that the RO7247669 injection being developed by Roche has been declared for clinical use in China and was accepted on July 2
Screenshot source: CDE official website
Bispecific antibody is an antibody that can specifically bind to two different antigens
RO7247669 is a bispecific antibody targeting PD-1 and LAG-3 developed by Roche
LAG-3 is called lymphocyte activation gene-3.
Information published on the Clinicaltrials.
Reference materials:
[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.